Preliminary results from Phase 1 data for LB2102 to reinforce early evidence of activity in solid tumors in a rapid oral presentation New data ...

Melanoma kills roughly 8,000 Americans each year, and a stubborn share of those deaths trace back to the same problem: tumors ...

A cut that would close in days on a 25-year-old can linger for weeks on a 75-year-old, and the usual explanations (thinner ...

New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.

By Julie Steenhuysen CHICAGO, May 31 (Reuters) - Revolution Medicine's experimental pancreatic cancer pill doubled survival compared with chemotherapy and improved symptoms enough that some patients ...

Those taking daraxonrasib lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients.

The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung, colon and ovarian cancers.

Revolution Medicines Inc.’s experimental pancreatic cancer drug daraxonrasib delayed painful symptoms for months, in addition ...

The TroFuse-005 trial involved 776 patients with endometrial cancer whose disease worsened after receiving both platinum ...

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

CAR-T cells are a patient's own T cells, a form of white blood cell, that have been genetically modified to recognize and ...

Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic ...